Table 2.
Meta-analysis of randomized controlled trials on the efficacy of tofacitinib in active RA
| Tofacitinib dosedose | Outcome | No. of Studies | Test of association |
Test of heterogeneity |
||||
|---|---|---|---|---|---|---|---|---|
| WMD | 95% CI | p value | Model | p value | I2 | |||
| Tofacitinib 5 mg, bid | ACR20 | 3 | 2.445a | 1.229 to 4.861 | 0.011 | R | 0.014 | 76.7 |
| Tender joint count | 3 | –5.731 | –8.054 to –3.048 | 1.3 × 10-7 | F | 0.279 | 21.6 | |
| Swollen joint count | 3 | –5.422 | –9.593 to –1.252 | 0.011 | R | 0.008 | 79.4 | |
| Pain (VAS) | 3 | –12.72 | –18.06 to –7.376 | 3.0 × 10-7 | F | 0.464 | 0 | |
| Patient global assessment | 3 | –17.82 | –28.20 to –7.444 | < 1.0 × 10-8 | R | 0.017 | 75.6 | |
| Physician global assessment | 3 | –17.88 | –26.48 to –9.286 | < 1.0 × 10-8 | R | 0.067 | 63.0 | |
| HAQ | 3 | –0.341 | –0.455 to –0.226 | < 1.0 × 10-8 | F | 0.526 | 0 | |
| CRP | 3 | –16.43 | –28.09 to –4.778 | 0.006 | R | 0.000 | 87.8 | |
| Tofacitinib 10 mg, bid | ACR20 | 3 | 2.597a | 1.514 to 4.455 | 0.001 | R | 0.054 | 65.8 |
| Tender joint count | 3 | –6.295 | –8.517 to –4.073 | 2.0 × 10-9 | F | 0.639 | 0 | |
| Swollen joint count | 3 | –5.970 | –9.630 to –2.311 | 0.001 | R | 0.010 | 78.5 | |
| Pain (VAS) | 3 | –18.20 | –29.50 to –8.230 | 0.002 | R | 0.020 | 74.5 | |
| Patient global assessment | 3 | –17.70 | –27.17 to –8.230 | < 1.0 × 10-8 | R | 0.044 | 68.0 | |
| Physician global assessment | 3 | –17.45 | –28.82 to –6.082 | 0.003 | R | 0.010 | 78.2 | |
| HAQ | 3 | –0.344 | –0.461 to –0.227 | < 1.0 × 10-8 | F | 0.143 | 48.5 | |
| CRP | 3 | –17.07 | –32.15 to –1.999 | 0.026 | R | 0.000 | 92.2 | |
WMD, weighted mean difference; CI, confidence interval; bid, twice daily; ACR20, American College of Rheumatology 20% response rate; R, random effects model; F, fixed effects model; VAS, visual analog scale; HAQ, Health Assessment Questionnaire; CRP, C-reactive protein.
a
Relative risk.